Epizyme (NASDAQ: EPZM) today reported key pipeline progress and 2018 milestones, as well as operating results for the quarter and year ended December 31, 2017. As quoted in the press release: “2017 was truly a transformational year for Epizyme as we moved several steps closer to bringing tazemetostat to patients with both solid tumors and …

Epizyme (NASDAQ: EPZM) today reported key pipeline progress and 2018 milestones, as well as operating results for the quarter and year ended December 31, 2017.

As quoted in the press release:

“2017 was truly a transformational year for Epizyme as we moved several steps closer to bringing tazemetostat to patients with both solid tumors and hematological malignancies,” said Robert Bazemore, president and chief executive officer of Epizyme. “These efforts have positioned Epizyme for one of the most milestone-rich years in the company’s history. We plan to submit our first NDA for tazemetostat for the treatment of patients with epithelioid sarcoma in the fourth quarter and are targeting a second NDA submission for the treatment of follicular lymphoma in 2019. We plan to present updated data from both of these programs this year, as well as from our studies in mesothelioma, diffuse large B-cell lymphoma, and other adult INI1-negative tumors. In addition, Epizyme will be readying its next product candidate, EZM8266, for the clinic. I am proud of our team’s many accomplishments and am confident in our ability to continue building momentum as we transition into a fully-integrated, commercial organization.”

Click here to read the full press release.